BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In contrast, dasatinib is an orally active dual BCR-ABL and broad Src family tyrosine kinase inhibitor (IC50: 0.4 nM LCK; 0.5 nM for Src and Yes) that is FDA-approved and currently indicated for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and Ph + acute lymphoblastic leukemia (ALL) [54].